Central Nervous System Lymphoma

Observed

→ investigated in trials for

Rituximabmonoclonal antibody

34 trials (15 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Lenalidomidesmall molecule

15 trials (6 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ibrutinibsmall molecule

13 trials (6 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Temozolomidesmall molecule

8 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nivolumabmonoclonal antibody

6 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Zanubrutinibsmall molecule

6 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cyclophosphamidesmall molecule

5 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cytarabinesmall molecule

5 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pemetrexedsmall molecule

5 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Acalabrutinibsmall molecule

4 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Dexamethasonesmall molecule

4 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Fludarabinesmall molecule

4 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Obinutuzumabmonoclonal antibody

4 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pembrolizumabmonoclonal antibody

4 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pomalidomidesmall molecule

4 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Procarbazinesmall molecule

3 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bimiralisibsmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Chemotherapy

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Durvalumabmonoclonal antibody

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Epcoritamabmonoclonal antibody

2 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Etoposidesmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Leucovorinsmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Prednisonesmall molecule

2 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sintilimabmonoclonal antibody

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Thiotepasmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Venetoclaxsmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Vorinostatsmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Akt Inhibitor MK2206

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Belinostatsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bendamustinesmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bortezomibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Buparlisibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Busulfansmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Camrelizumabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Capecitabinesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Carboplatinsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Carmustinesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Copanlisibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Dordavipronesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Doxorubicinsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Everolimussmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Filgrastimother

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Gemcitabinesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Glofitamabmonoclonal antibody

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Imatinib Mesylatesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Irinotecansmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Panobinostatsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Polatuzumab Vedotinadc

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Selinexorsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tafasitamabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tanespimycinsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Teniposidesmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tisagenlecleucelcell therapy

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tislelizumabmonoclonal antibody

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Topotecansmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Vincristinesmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Vismodegibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

Central Nervous System Lymphoma studied in …STUDIED_INderived10 of 214show all (up to 200)
→ studied in	NCT07839247Phase 2 · recruiting Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSL · condition mapped ONTOLOGY_EXACT · 214 trials mapped (90 active)	—	—	Primary Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07842835not yet recruiting Registry of an Integrated Longitudinal Multimodal Biospecimen Biobank for Primary CNS Lymphoma in China (CLIMB) · condition mapped ONTOLOGY_EXACT · 214 trials mapped (90 active)	—	—	Primary Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06175000Phase 2 · recruiting Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response · condition mapped ONTOLOGY_EXACT · 214 trials mapped (90 active)	—	—	Primary Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04688151Phase 1 · completed Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma. · condition mapped ONTOLOGY_EXACT · 214 trials mapped (90 active)	—	—	Primary Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04462328Phase 1 · active not recruiting Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (90 active)	—	—	Primary Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03964090Phase 2 · active not recruiting Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) · condition mapped ONTOLOGY_EXACT · 214 trials mapped (90 active)	—	—	Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04609046Phase 1 · active not recruiting Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (90 active)	—	—	Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System	1	Observed	clinicaltrials	graph →
→ studied in	NCT02203526Phase 1 · active not recruiting Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (90 active)	—	—	Primary Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04464200Phase 1 · active not recruiting 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers · condition mapped ALIAS · 214 trials mapped (90 active)	—	—	Primary Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07608731Phase 1 · not yet recruiting Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas · condition mapped ONTOLOGY_EXACT · 214 trials mapped (90 active)	—	—	Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →

Central Nervous System Lymphoma studied in …STUDIED_INderived10 of 214show all (up to 200)

→ studied in

NCT07839247Phase 2 · recruiting

Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSL · condition mapped ONTOLOGY_EXACT · 214 trials mapped (90 active)

—

Observed

→ studied in

NCT07842835not yet recruiting

Registry of an Integrated Longitudinal Multimodal Biospecimen Biobank for Primary CNS Lymphoma in China (CLIMB) · condition mapped ONTOLOGY_EXACT · 214 trials mapped (90 active)

—

Observed

→ studied in

NCT06175000Phase 2 · recruiting

Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response · condition mapped ONTOLOGY_EXACT · 214 trials mapped (90 active)

—

Observed

→ studied in

NCT04688151Phase 1 · completed

Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma. · condition mapped ONTOLOGY_EXACT · 214 trials mapped (90 active)

—

Observed

→ studied in

NCT04462328Phase 1 · active not recruiting

Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (90 active)

—

Observed

→ studied in

NCT03964090Phase 2 · active not recruiting

Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) · condition mapped ONTOLOGY_EXACT · 214 trials mapped (90 active)

—

Observed

Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

→ studied in

NCT04609046Phase 1 · active not recruiting

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (90 active)

—

Observed

→ studied in

NCT02203526Phase 1 · active not recruiting

Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (90 active)

—

Observed

→ studied in

NCT04464200Phase 1 · active not recruiting

19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers · condition mapped ALIAS · 214 trials mapped (90 active)

—

Observed

→ studied in

NCT07608731Phase 1 · not yet recruiting

Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas · condition mapped ONTOLOGY_EXACT · 214 trials mapped (90 active)

—

Observed